Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Advances of antibody therapy in ALL

David Marks • 4 Dec 2020
ASH 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin

David Marks, MB, MS, FRACP, PhD, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses the recent advances in antibody therapy in acute lymphoblastic leukemia (ALL). Exciting developments have come from the novel antibodies blinatumomab and inotuzumab, as well as the development of CAR T-cell therapy. Additionally, inotuzumab and blinatumomab are both major advances in relapsed/refractory ALL. Antibody chemotherapy combinations also offer significant clinical benefit for older patients with Philadelphia positive ALL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from David Marks

The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
The importance of MRD assessment before alloSCT in ALL
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals